Are there any challenges in using nanoparticles for PD-L1 targeting?
Despite the promising potential, there are several challenges in using nanoparticles for PD-L1 targeting: - Biocompatibility and potential toxicity of nanoparticles. - Immune system evasion, where nanoparticles can be recognized and cleared by the immune system before reaching the tumor site. - Difficulty in achieving precise targeting and avoiding off-target effects. - Scale-up and reproducibility of nanoparticle synthesis for clinical applications.
